Conference Report

New Data on HBV Disease

Source: CCO Independent Conference Coverage of the Asian Pacific Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

New Data on HBV Disease

CME Program Director: Robert G. Gish, MD

Faculty:

Robert G. Gish, MD
George K. K. Lau, MD

CME CREDIT INFORMATION

Release Date: 12/09/05

Expiration Date: 12/08/06

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss new data on the relationship between pharmacologic parameters and clinically relevant treatment outcomes.
Discuss a comparison of the efficacy, sustainability, and costeffectiveness of various treatment regimens.
Describe recent insights into the pharmacology of investigational anti-HBV agents.

Topics covered include:

Overview
Association Between TLR7 Expression and HBsAg Clearance
Comparing the Efficacy of Entecavir vs Lamivudine in China
Safety of Entecavir for Treatment-Naive and Lamivudine-Refractory Patients With Chronic HBV
Durability of Response: Entecavir Studies 022 and 027
Durability of Peginterferon Alfa-2a Response in Asian Populations
Durability of Peginterferon Alfa-2a Response
Off-Therapy Durability of Response After 24 Weeks of Clevudine
Use of Preemptive Lamivudine Prior to Chemotherapy
Combination Treatment With Peginterferon Alfa-2a Plus Lamivudine
HBeAg Loss With Interferon Plus Thymosin Alpha 1
Cost-effectiveness of Peginterferon alfa-2a vs Lamivudine
REVEAL: HBV DNA Level as a Predictor for HCC and Cirrhosis

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.